Immunocore announced that the TEBE-AM Phase 2/3 clinical trial has been converted into a Phase 3 trial. The Phase 2/3 TEBE-AM trial was designed to evaluate KIMMTRAK, as monotherapy and in combination with pembrolizumab, versus a control arm, for the treatment of patients with previously treated advanced cutaneous melanoma. The registrational TEBE-AM trial was initiated following results from a Phase 1b trial of tebentafusp in combination with checkpoint inhibitors in metastatic cutaneous melanoma. The Phase 1b data showed that the maximum target doses of tebentafusp plus durvalumab were well tolerated, and that, in mCM patients who progressed on prior anti-PD(L)1, the combination demonstrated a one-year overall survival rate of ~75%.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
- Immunocore Bolsters Board and Strikes Deal with BBA Funds
- Immunocore price target lowered to $88 from $90 at Mizuho
- Immunocore price target raised to $100 from $90 at H.C. Wainwright
- Immunocore price target raised to $67 from $63 at Canaccord